Methods for treating immunodeffect disease

The small molecule antagonist of CXCR4 blocked the signaling of CXCR4 receptor, which solved the problem of low white blood cell count in WHIM syndrome, significantly improved the patient's immune function and white blood cell count, and achieved a lower toxic therapeutic effect .

CN118948848APending Publication Date: 2024-11-15X4 PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411031201.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-12-01
Filing Date
2016-12-22
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing treatment methods for WHIM syndrome have problems that are nonspecific, expensive and only partially effective, and it is difficult to effectively improve patients' white blood cell count and immune function.

Method used

Using CXCR4's small molecule antagonist X4P-001, the enhanced signaling activity of CXCR4 receptors is blocked through oral pathways, the number of circulating white blood cells is increased, the binding of SDF-1α to CXCR4 is inhibited, and the release of neutrophils and lymphocytes is improved. , thereby improving the patient's immune function.

Benefits of technology

The patient's neutrophil and lymphocyte counts were significantly increased, the immune system function was improved, the infection frequency was reduced, and a lower toxic effect was achieved due to its specific targeting.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948848A_ABST
    Figure CN118948848A_ABST
Patent Text Reader

Abstract

The present application relates to methods for treating immunodeficiency disease. The present invention relates to methods of treating a patient suffering from WHIM syndrome or a related disorder, such as neutrophil bone marrow retention, in which X4P-001 is administered to reduce the activity of CXCR4. The methods exhibit unexpected efficacy, with relatively low toxicity.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application date of December 22, 2016, application number 201680079620.6, and name “Method for treating immunodeficiency disease”. Technical Field

[0002] The present invention relates to methods for treating immunodeficiency diseases, and in particular methods for treating warts, hypogammaglobulinemia, immunodeficiency, neutrophil bone marrow retention (WHIM) syndrome or "WHIMS." WHIMS is a disease characterized by neutropenia and lymphopenia that leads to skin and genital warts and recurrent infections.

[0003] CROSS-REFERENCE TO RELATED APPLICATIONS

[0004] This application claims the benefit of priority to U.S. Provisional Patent Application No. USSN 62 / 271,087, filed December 22, 2015, and No. USSN 62 / 428,964, filed December 1, 2016, the entire contents of each of which are incorporated herein by reference. Background Art

[0005] WHIM syndrome is a rare autosomal dominant immunodeficiency disorder that results in multiple mutations that remove 10 to 19 amino acids from the carboxyl terminus of CXCR4, a chemokine receptor expressed by both hematopoietic and non-hematopoietic cells [Hernandez 2003]. Mutations in the CXCR4 receptor are known to prevent the normal release of mature neutrophils from the bone marrow into the blood [Kawai 2005], which results in neutropenia in patients with WHIM syndrome [Dale 2011]. In addition to neutropenia, WHIM syndrome is also characterized by lymphocytopenia that affects circulating levels of circulating T cells and B cells [Balabanian 2012, Dotta 2011] resulting in low levels of immunoglobulins. The exact mechanism of lymphocytopenia remains unclear but may be attributed to disruption of the normal trafficking of lymphocytes and their retention in the bone marrow and other lymphoid tissues [Ma 1999].

[0006] Typically, clinical symptoms first appear in early childhood with recurrent bacterial infections due to low levels of white blood cells and antibodies [NORD 2015]. Common infections include otitis media, cellulitis, impetigo, abscesses, bacterial pneumonia, sinusitis, and periodontitis. Affected individuals are particularly susceptible to infection with human papillomavirus (HPV), which can cause widespread warts that affect the hands, feet, face, and trunk and are often persistent [NORD 2015]. Mucosal and genital warts can also develop, and these warts are associated with an increased risk of developing cervical cancer [NORD 2015]. Current treatments include G-CSF and intravenous immunoglobulin, but these treatments are nonspecific, expensive, difficult to administer, and only partially effective [Kawai 2009].

[0007] Currently available treatments for WHIM syndrome patients are inadequate. There is a clear unmet need for agents that improve treatment outcomes for such patients. Summary of the invention

[0008] The present invention relates to a method for treating WHIM syndrome in a patient in need thereof, wherein the method comprises administering to the patient an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 X4P-001 inhibition of SDF-1α binding to CXCR4+CEM-CCRF cells is shown.

[0010] Figure 2 X4P-001 inhibition of SDF-1α stimulated Eu-GTP binding is shown.

[0011] Figure 3 The results showed that the SDF-1α-stimulated 35 S]-GTP-γ-S binding by X4P-001.

[0012] Figure 4 Shown is X4P-001 inhibition of SDF-1α-induced calcium flux.

[0013] Figure 5 X4P-001 inhibition of SDF-1α stimulated CCRF-CEM chemotaxis is shown.

[0014] Figure 6 Shown is SDF-1α stimulation of calcium flux in wild type and CXCR4 variants.

[0015] Figure 7 Shown is X4P-001 inhibition of SDF-1α stimulation in wild-type and CXCR4 variants.

[0016] Figure 8 Shown are the leukocyte (A), neutrophil (B), and lymphocyte (C) counts in male beagle dogs following oral administration of X4P-001.

[0017] Fig. 9 A dose-dependent increase (2-fold to 3-fold) in WBC counts was shown in human subjects administered X4P-001. DETAILED DESCRIPTION

[0018] An effective targeted therapy for WHIM syndrome, such as X4P-001, is necessary for the management of patients. X4P-001 can be administered orally, which, in addition to being a targeted therapy, makes it an excellent candidate in the chronic treatment setting required for WHIM syndrome patients.

[0019] The ligand for the CXCR4 receptor is SDF-1α, which is involved in many physiological processes and plays a central role in the homing of hematopoietic cells to and release from the bone marrow [Lapidot 2002]. Mutations in CXCR4 prevent the normal release of mature neutrophils from the bone marrow into the blood [Kawai 2005]. Bone marrow examination of patients with WHIM syndrome shows a large number of neutrophils with hypersegmented nuclei and remnants of neutrophils found in bone marrow macrophages [Bohinjec 1981].

[0020] Disruption of the CXCR4 / SDF-1α axis results in low white blood cell counts in WHIM syndrome patients, usually <1.0 x 10 9 1 / L, with severe neutropenia and lymphopenia [Dale 2011]. The following paragraphs describe the mechanism of disruption of the CXCR4 / SDF-1α axis.

[0021] CXCR4 is a G protein-coupled receptor, and engagement of SDF-1α induces the classic activation of G protein-dependent pathways of chemokine receptors [Baggiolini 1998, Zlotnik 2000]. These processes are regulated in a timely manner by the recruitment of β-arrestin to the receptor, which prevents further G protein activation (i.e., desensitization) and leads to receptor internalization. The CXCR4 mutants associated with WHIM syndrome cause impaired desensitization and internalization of the receptor upon SDF-1α exposure, resulting in enhanced and prolonged activation of the receptor. [Hernandez 2003, Balabanian 2005, Gulino 2004, Kawai 2005, Lagane 2008, McCormick 2009]. Because CXCR4 normally regulates leukocyte trafficking and is particularly important for neutrophil adhesion in the bone marrow, prolonged activity of SDF-1α-dependent signaling is a possible cause of the neutrophil bone marrow sparing (MKX) and neutropenia seen in WHIM syndrome [McDermott 2011-a].

[0022] X4P-001 is a small molecule antagonist of CXCR4 that has the potential to block the enhanced signaling activity of mutant CXCR4, leading to increased numbers of circulating leukocytes by overcoming the impaired downregulation (receptor internalization) and receptor dysfunction caused by mutant CXCR4 (McDermott 2011-b). X4P-001 has also been shown to inhibit the most common CXCR4 genotype forms attributable to WHIM syndrome (R334X and E343X) to a similar extent as wild-type CXCR4 [Mosi 2012].

[0023] These studies showed that oral administration of up to 400 mg BID for 3.5 days (healthy volunteers) and 200 mg BID for 8 to 10 days (healthy volunteers and HIV patients) was well tolerated with no pattern of adverse events or clinically significant laboratory changes. These studies also showed pharmacodynamic activity with dose-related and concentration-related changes in circulating white blood cells (WBC); and a high volume distribution (VL), indicating high tissue penetrance.

[0024] The inventors believe that X4P-001's antagonism of CXCR4 could provide significant therapeutic benefit to WHIMS patients, as well as patients with various aspects of WHIMS, an acronym for warts, hypogammaglobulinemia (low immunoglobulin levels), immunodeficiency (susceptibility to infection), and neutrophilic myeloretention (trapping of white blood cells in the bone marrow). Administration of X4P-001 inhibits the binding of SDF-1α to CXCR4 and CXCR4+CEM-CCRF cells. [See Figure 1 Administration of X4P-001 also inhibited CXCR4 cell signaling and SDF-1α-induced calcium flux. [See Figures 2 to 4 ]. In this way, X4P-001 inhibits SDF-1α-stimulated CCRF-CEM chemotaxis. [See Figure 5 ].

[0025] In addition, the inventors believe that since CXCR4-targeted drugs are specifically targeted and do not induce cell cycle arrest in normal proliferating cell populations, this result can be achieved with relatively little toxicity. Therefore, the present invention utilizes the low toxicity and action of the CXCR4 inhibitor AMD11070 (X4P-001) to provide significant advantages in therapeutic results.

[0026] In the present invention, patients suffering from WHIMS, or a related syndrome, are treated with X4P-001, or a pharmaceutically acceptable salt or composition thereof, either as a single agent treatment (monotherapy) or in combination with another agent, such as granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF) or intravenous immunoglobulin (IVIG).

[0027] In some embodiments, the present invention provides a method for treating WHIMS in a patient in need thereof, wherein the method comprises administering to the patient X4P-001 or a pharmaceutically acceptable salt or composition thereof in combination with G-CSF, GM-CSF and / or IVIG. Other treatments that may be used for the treatment of WHIMS include bone marrow transplantation and cord blood stem cell therapy.

[0028] In some embodiments, provided methods include administering X4P-001 or a pharmaceutically acceptable salt or composition thereof to a patient in a fasting state.

[0029] In certain embodiments, the present invention provides a method for treating WHIMS in a patient in need thereof, wherein the method comprises administering X4P-001 or a pharmaceutically acceptable salt or composition thereof to the patient, and the method further comprises the step of obtaining a biological sample from the patient and measuring the amount of a biomarker associated with the disease. In some embodiments, the biological sample is a blood sample. In certain embodiments, the biomarker associated with the disease is selected from the group consisting of CXCR4, SDF-1α / CXCL12; and GRK3 (G protein coupled receptor kinase 3).

[0030] In some embodiments, the present invention provides a method for treating WHIMS in a patient in need thereof, wherein the method comprises administering X4P-001 or a pharmaceutically acceptable salt or composition thereof to the patient.

[0031] In some embodiments, X4P-001 or a pharmaceutically acceptable salt thereof is administered at a dose of about 25 mg / day to about 150 mg / day.

[0032] In some embodiments, the patient presents with warts.

[0033] In some embodiments, cells removed from a patient express a mutant form of CXCR4.

[0034] In some embodiments, cells removed from a patient exhibit increased expression of CXCR4.

[0035] In some embodiments, the method further comprises the step of obtaining a biological sample from the patient and measuring the amount of a biomarker associated with the disease.

[0036] In some embodiments, the biological sample is a blood sample.

[0037] In some embodiments, the disease-associated biomarker is circulating CXCR4.

[0038] In some embodiments, X4P-001 or a pharmaceutically acceptable salt or composition thereof is administered orally once a day.

[0039] In some embodiments, X4P-001 or a pharmaceutically acceptable salt thereof, or a composition thereof is administered orally twice daily.

[0040] In some embodiments, the present invention provides a unit dosage form comprising a composition comprising:

[0041] (a) X4P-001 or a pharmaceutically acceptable salt thereof - about 10 to 20% by weight of the composition;

[0042] (b) microcrystalline cellulose - about 70 to 85% by weight of the composition;

[0043] (d) croscarmellose sodium - about 5 to 10% by weight of the composition;

[0044] (e) sodium stearyl fumarate - about 0.5 to 2% by weight of the composition; and

[0045] (f) Colloidal silicon dioxide - about 0.1 to 1.0 wt % of the composition.

[0046] In some embodiments, the unit dosage form is in the form of a capsule.

[0047] In some embodiments, the capsule contains about 25 mg of X4P-001 or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, the present invention provides methods for treating WHIM syndrome in a patient in need thereof, comprising the step of administering to the patient a disclosed unit dosage form.

[0049] In some embodiments, the present invention provides a method for treating WHIM syndrome in a patient in need thereof, the method comprising administering X4P-001 or a pharmaceutically acceptable salt thereof or a composition to the patient in an amount effective to increase the absolute neutrophil count (ANC) and / or increase the absolute lymphocyte count (ALC) in the patient (e.g., in the patient's blood). In some embodiments, the ANC and / or ALC in the patient is increased to about 60%, 70%, 80%, 90%, 95%, or 100% of the ANC and / or ALC of an average healthy person who does not suffer from WHIM syndrome or another immune deficiency. In some embodiments, the ANC and / or ALC in the patient is increased to about 60%, 70%, 80%, 90%, 95%, or 100% of the ANC and / or ALC of an average healthy person of similar age, weight, and sex to the patient.

[0050] In some embodiments, the present invention provides a method for treating WHIM syndrome in a patient in need thereof, comprising administering to the patient an amount of X4P-001 or a pharmaceutically acceptable salt thereof, or a composition thereof, effective to increase the absolute neutrophil count (ANC) to a level greater than or equal to 600 / microliter and / or to increase the absolute lymphocyte count (ALC) to a level greater than or equal to 1000 / microliter.

[0051] In some embodiments, prior to treatment with X4P-001, the patient initially exhibits an ANC of less than 600 cells / microliter and / or an ALC of less than 1000 cells / microliter.

[0052] In some embodiments, prior to treatment with X4P-001, the patient initially exhibits an ANC of less than 400 cells / microliter and / or an ALC of less than 650 cells / microliter.

[0053] In some embodiments, the disclosed methods increase ANC levels to at least about 600 cells / microliter, about 800 cells / microliter, about 1000 cells / microliter, about 1,200 cells / microliter, or to about the ANC level of a human with a normally functioning immune system in at least 85% of the evaluations.

[0054] In some embodiments, the disclosed methods result in an increase in ALC to at least about 1000, about 1,200, or about 1,500 cells / microliter or to about the ALC level of a human with a normally functioning immune system in at least 85% of the evaluations.

[0055] In some embodiments, the disclosed methods result in increased levels of protective antibody response to a vaccine in a patient.

[0056] In some embodiments, the disclosed methods result in a reduction in the frequency of infections in a patient, such as at least a 50% reduction in infections, such as respiratory tract infections.

[0057] In some embodiments, the disclosed methods increase the level of total circulating WBC, neutrophils and / or lymphocytes. In some embodiments, the cell count of WBC, neutrophils and / or lymphocytes increases to at least 1.4 times of baseline. In some embodiments, the cell count of WBC, neutrophils and / or lymphocytes increases to at least 1.8 times of baseline. In some embodiments, the cell count of WBC, neutrophils and / or lymphocytes increases to at least 2.9 times of baseline. In some embodiments, the cell count of lymphocytes increases to at least 2.9 times of baseline. In some embodiments, the cell count of neutrophils increases to at least 2.7 times of baseline, and the cell count of lymphocytes increases to at least 1.9 times of baseline.

[0058] In some embodiments, the present invention provides a method for treating WHIMS in a patient in need thereof, wherein the method comprises administering to the patient an effective amount of X4P-001 or a pharmaceutically acceptable salt or composition thereof in conjunction with another treatment for warts, HPV infection, or neutropenia.

[0059] Dosage and preparation

[0060] X4P-001 is a CXCR4 antagonist with a molecular formula of C21H27N5; a molecular weight of 349.48 atomic mass units; an appearance of a white to light yellow solid; solubility: X4P-001 is easily soluble (>100 mg / ml) in the pH range of 3.0 to 8.0, poorly soluble (10.7 mg / ml) at pH 9.0, and slightly soluble (2.0 mg / ml) at pH 10.0. X4P-001 is only slightly soluble in water; the melting point is 108.9°ΔC.

[0061] The chemical structure of X4P-001 is depicted below.

[0062]

[0063] In certain embodiments, the composition containing X4P-001 is orally administered in an amount of about 10 mg to about 600 mg per day. In certain embodiments, the dosage composition can be provided twice a day in divided doses, approximately 12 hours apart. In other embodiments, the dosage composition can be provided once a day. The terminal half-life of X4P-001 is generally determined to be about 12 to about 24 hours, or approximately 14.5 hours. The dose for oral administration can be about 10 mg to about 300 mg, once or twice a day. In certain embodiments, the dosage of X4P-0001 that can be used in the present invention is about 20 mg to about 600 mg per day. In other embodiments, the dosage of X4P-001 that can be used in the present invention can be about 25 mg to about 200 mg per day, about 25 mg to about 150 mg per day, about 25 mg to about 100 mg per day, about 25 mg to about 50 mg per day, about 50 mg to about 150 mg per day, or about 50 mg to about 100 mg per day.

[0064] In some embodiments, provided methods include administering to a patient a pharmaceutically acceptable composition comprising X4P-001, wherein the composition is formulated for oral administration. In certain embodiments, the composition is formulated for oral administration in the form of a tablet or capsule. In some embodiments, the composition comprising X4P-001 is formulated for oral administration in the form of a capsule.

[0065] In certain embodiments, provided methods include administering to a patient one or more capsules comprising 10 mg to 1200 mg of X4P-001 active ingredient; and one or more pharmaceutically acceptable excipients. In certain embodiments, the capsules consist of hard gelatin.

[0066] In certain embodiments, the present invention provides a composition comprising X4P-001 or a pharmaceutically acceptable salt thereof, one or more diluents, disintegrants, lubricants, glidants, and wetting agents. In some embodiments, the present invention provides a composition comprising 10 mg to 1200 mg of X4P-001, or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, calcium hydrogen phosphate dihydrate, croscarmellose sodium, sodium stearyl fumarate, colloidal silicon dioxide, and sodium lauryl sulfate. In some embodiments, the present invention provides a unit dosage form, wherein the unit dosage form comprises a composition containing 10 to 200 mg of X4P-001, or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, calcium hydrogen phosphate dihydrate, croscarmellose sodium, sodium stearyl fumarate, colloidal silicon dioxide, and sodium lauryl sulfate. In certain embodiments, the present invention provides a unit dosage form comprising a composition containing X4P-001 or a pharmaceutically acceptable salt thereof, wherein the X4P-001 or a pharmaceutically acceptable salt thereof is present in an amount of about 10 mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 400 mg, about 450 mg, about 500 mg, about 600 mg, about 700 mg, about 750 mg, about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, or about 1200 mg. In some embodiments, the provided composition (or unit dosage form) is administered to a patient once a day, twice a day, three times a day, or four times a day. In some embodiments, the provided composition (or unit dosage form) is administered to a patient once a day or twice a day.

[0067] In some embodiments, the present invention provides a unit dosage form comprising a composition comprising:

[0068] (a) X4P-001 or a pharmaceutically acceptable salt thereof - about 10 to 30% by weight of the composition;

[0069] (b) microcrystalline cellulose - about 60 to 80% by weight of the composition;

[0070] (c) croscarmellose sodium - about 5 to 10% by weight of the composition;

[0071] (d) sodium stearyl fumarate - about 0.5 to 2% by weight of the composition; and

[0072] (e) Colloidal Silica - about 0.1 to 1.0 wt % of the composition.

[0073] In some embodiments, the present invention provides a unit dosage form comprising a composition comprising:

[0074] (a) X4P-001 or a pharmaceutically acceptable salt thereof - about 14.7% by weight of the composition;

[0075] (b) microcrystalline cellulose - about 78.1% by weight of the composition;

[0076] (c) croscarmellose sodium - about 6.0% by weight of the composition;

[0077] (d) sodium stearyl fumarate - about 1.0% by weight of the composition; and

[0078] (e) Colloidal Silica - about 0.2% by weight of the composition.

[0079] In some embodiments, the present invention provides a unit dosage form comprising a composition comprising:

[0080] (a) X4P-001 or a pharmaceutically acceptable salt thereof - about 10 to 20% by weight of the composition;

[0081] (b) microcrystalline cellulose - about 25 to 40% by weight of the composition;

[0082] (c) calcium hydrogen phosphate dihydrate - about 35 to 55% by weight of the composition;

[0083] (d) croscarmellose sodium - about 4 to 15% by weight of the composition;

[0084] (e) sodium stearyl fumarate - about 0.3 to 2% by weight of the composition;

[0085] (f) colloidal silicon dioxide - about 0.1 to 1.5% by weight of the composition; and

[0086] (g) Sodium Lauryl Sulfate - about 0.1 to 1.5 wt % of the composition.

[0087] In some embodiments, the present invention provides a unit dosage form comprising a composition comprising:

[0088] (a) X4P-001 or a pharmaceutically acceptable salt thereof - about 12.85% by weight of the composition;

[0089] (b) microcrystalline cellulose - about 31.92% by weight of the composition;

[0090] (c) calcium hydrogen phosphate dihydrate - about 44.4% by weight of the composition;

[0091] (d) croscarmellose sodium - about 8.33% by weight of the composition;

[0092] (e) sodium stearyl fumarate - about 1.38% by weight of the composition;

[0093] (f) colloidal silicon dioxide - about 0.42% by weight of the composition; and

[0094] (g) Sodium Lauryl Sulfate - about 0.7% by weight of the composition.

[0095] Since it may be desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound according to the present invention, can be conveniently combined in the form of a kit suitable for co-administration of the composition. Thus, the kit of the present invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound according to the present invention, and means for separately retaining the compositions, such as a container, a split bottle or a split foil package. An example of such a kit is a common blister package for packaging tablets, capsules, etc.

[0096] The kit of the invention is particularly suitable for administering different dosage forms (e.g., oral dosage forms and parenteral dosage forms), administering separate compositions at different dosage intervals, or titrating separate compositions against each other. To aid compliance, the kit typically includes instructions for administration and may be provided with a memory aid.

[0097] The examples below illustrate the present invention in more detail. The following preparations and examples are given to enable those skilled in the art to more clearly understand and practice the present invention. However, the present invention is not limited to the scope of exemplary embodiments, which are only intended to illustrate a single aspect of the present invention, and functionally equivalent methods are within the scope of the present invention. In fact, according to the foregoing description and the accompanying drawings, in addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art. Such modifications are intended to fall within the scope of the appended claims.

[0098] The contents of each document cited in the specification are hereby incorporated by reference in their entirety.

[0099] example

[0100] Example 1: Non-clinical evaluation of the effect of X4P-001 on CXCR4:

[0101] In vitro pharmacology

[0102] The in vitro pharmacology of X4P-001 (formally known as AMD11070) was extensively studied and the results reported [Moshi 2012]. Provided below is relevant information from the Moshi 2012 literature publication. The SDF-1α isoform was used in the experiments described below.

[0103] X4P-001 inhibits the binding of SDF-1α to CXCR4

[0104] In heterologous competition binding assays, X4P-001 was shown to inhibit [ 125 I]-SDF-1α binding to CCRF-CEM cells (a T lymphoblastoid cell line that naturally expresses CXCR4 [Crump 1997]). The results of the assay are shown below Figure 2 Fitting the data to a single-site binding model yielded an IC of 12.5 ± 1.3 nmol 50 .

[0105] X4P-001 inhibits CXCR4 cell signaling

[0106] CXCR4 is a G protein-coupled receptor [Baggiolini 1998, Zlotnik 2000]. Therefore, non-hydrolyzable analogs of GTP (e.g., fluorescently labeled europium-GTP (Eu-GTP) or radiolabeled [ 35 S]-GTPγS) to measure receptor activation. Figure 3 and Figure 4 The results shown in the Figure 2 indicate that X4P-001 has a significant activity in Eu-GTP binding and [ 35 S]-GTPγS assay inhibited CXCR4 activation, IC 50 The values ​​were 39.8±2.5 nmol / L and 19.0±4.1 nmol / L, respectively.

[0107] Upon activation of GPCRs, intracellular signaling pathways are triggered, resulting in the release of calcium from intracellular stores. This calcium flux can be measured using the calcium chelating molecule Fluo-4, which fluoresces when bound to calcium. X4P-001 is able to inhibit SDF-1α (2.5 nmol / L SDF-1α)-mediated calcium flux in CCRF-CEM cells, with an IC 50 The results are shown in Figure 5 middle.

[0108] A key property of all chemokines is that they induce a chemotactic response to chemokine concentration gradients. Figure 6 As shown in Figure 2, X4P-001 was able to inhibit SDF-1α-mediated chemotaxis of CCRF-CEM cells. 50 It is 19.0±4.0 nanomol / L.

[0109] The above in vitro results are summarized in Table 1 below:

[0110] Table 1: X4P-001 in vitro concentrations associated with different biological responses (IC 50 )

[0111]

[0112]

[0113] a = Results are expressed as mean ± SE

[0114] Selectivity of X4P-001 for CX4

[0115] To demonstrate the specificity of X4P-001 for CXCR4, it was tested in calcium signaling assays against a panel of chemokine receptors and in ligand binding assays for BLT1, leukotriene B4 (LTB4) receptor, and CXCR7. LTB4 is a potent chemoattractant whose receptor is a G protein-coupled receptor. The results in Table 2 show that in all cases, X4P-001 had an IC of 1.0 for CCR1, CCR2b, CCR4, CCR5, CCR7, CXCR3, and LTB4. 50 >50 mmol / L. X4P-001 did not inhibit SDF-1α binding to CXCR7 at a concentration of 10 mmol / L, the maximum concentration tested in this assay. Together these data suggest that X4P-001 is a selective inhibitor of CXCR4.

[0116] To demonstrate the specificity of X4P-001 for CXCR4, it was tested in calcium signaling assays against a panel of chemokine receptors and in ligand binding assays for BLT1, leukotriene B4 (LTB4) receptor, and CXCR7. LTB4 is a potent chemoattractant whose receptor is a G protein-coupled receptor. The results in Table 2 show that in all cases, X4P-001 had an IC of 1.0 for CCR1, CCR2b, CCR4, CCR5, CCR7, CXCR3, and LTB4. 50 >50 mmol / L. X4P-001 did not inhibit SDF-1α binding to CXCR7 at a concentration of 10 mmol / L, the maximum concentration tested in this assay. Together these data suggest that X4P-001 is a selective inhibitor of CXCR4.

[0117] Table 2: For IC 50 Calcium flux responses of cell lines treated with X4P-001 as measured

[0118]

[0119] X4P-001 inhibits the C-terminal variant of CXCR4

[0120] From a therapeutic perspective, it is important that CXCR4 antagonists can act against CXCR4 variants. Variants of CXCR4 with carboxy-terminal truncations have been reported to be associated with WHIM syndrome; a nonsense mutation resulting in a 19 amino acid truncation (R334X) and a nonsense mutation resulting in a 10 amino acid truncation (E343X) as well as a frameshift mutation resulting in a 13 amino acid truncation (S339fs342X) [Hernandez 2003, Kawai 2009]. The R334X and E343X CXCR4 variants were cloned and transiently expressed in the canine thymic cell line Cf2Th. This cell line was chosen due to its lack of CXCR4 expression [Wong 2008]. Wild-type CXCR4 was similarly subcloned into this cell line for control studies. In control studies, these carboxy-terminal truncated variants were demonstrated to be able to respond to SDF-1α in a calcium flux assay with similar potency to wild-type CXCR4. EC values ​​of SDF-1α for wild-type, R334X, and E343X variants of CXCR4 50 The values ​​were 13.6, 11.3 and 15.3 nmol / L respectively ( Figure 6 ). The inhibitory effect of X4P-001 on SDF-1α-mediated calcium flux was evaluated for two CXCR4 variants. Both variants inhibited to a similar extent as wild-type CXCR4, with IC values ​​of wild-type, R334X, and E343X variants. 50 The values ​​were 3.1, 8.5 and 4.6 nmol / L ( Figure 7 ).

[0121] Discussion and conclusions based on in vitro studies

[0122] Using the CCRF-CEM cell line that naturally expresses CXCR4 [Crump 1997], it was shown that X4P-001 inhibits the binding of SDF-1α ligand to CXCR4, IC 50 X4P-001 also inhibited CXCR4 activation and signaling as follows: 35 S]-GTPγS binding assay inhibits SDF-1α-mediated G protein activation of CXCR4 receptor in two assays, IC 50 The values ​​were 39.8 ± 2.5 nmol / L and 19.0 ± 4.1 nmol / L, respectively, and the inhibition of SDF-1α-mediated calcium flux, IC 50 9.0±2.0 nmol / L. X4P-001 also inhibits SDF-1α-mediated chemotaxis, CXCR4-mediated physiological responses, IC 5019.0 ± 4.0 nanomoles / liter. In addition, X4P-001 has little or no inhibitory effect on calcium flux mediated by MIP1α, MCP-1, TARC, RANTES, MIP-3β or IP10, ligands for CCR1, CCR2b, CCR4, CCR5, CCR7 and CXCR3, or on SDF-1α binding to CXCR7, or on LTB4 binding to BLT1, respectively. BLT1 is an alternative, chemotactic G protein-coupled receptor. These data indicate that X4P-001 is a selective inhibitor of CXCR4 (rather than other chemokine receptors evaluated).

[0123] Mutations in CXCR4 that result in truncations of the intracellular carboxyl terminus of the receptor are associated with the rare disease, WHIM syndrome [Hernandez 2003, Kawai 2009]. Two of these CXCR4 variants were evaluated, and the results showed that X4P-001 was able to inhibit SDF-1α-mediated calcium flux in these carboxyl-terminally truncated variants. These data also suggest that X4P-001 acts through interaction with the extracellular region of CXCR4. Furthermore, from the perspective of X4P-001 as a potential treatment for WHIM syndrome, it is important that it can inhibit multiple variants of CXCR4.

[0124] Furthermore, by comparing the dose / response of SDF-1α in the presence of increasing amounts of X4P-001 in a calcium flux assay, X4P-001 was shown to be an allosteric inhibitor of CXCR4 [Moshi 2012]. Based on the inhibition being mediated by noncompetitive binding, the extent of inhibition depends only on the concentration of X4P-001 and is independent of the concentration of the SDF-1α ligand.

[0125] In vivo pharmacology

[0126] The major in vivo pharmacological effect of X4P-001 is the mobilization of white blood cells (WBC) from the bone marrow. Summarized below are three studies that demonstrated the mobilization of WBC from the bone marrow of beagle dogs and C3W / He J mice.

[0127] Hematologic Effects in Male Beagles

[0128] Three fasting male beagle dogs received a single dose of X4P-001 in aqueous solution by oral gavage at dose levels of 5, 15, and 35 mg / kg in a volume of 1 μL / kg (1 dog per dose level). Blood samples (approximately 3 mL each) were obtained from each animal by direct venipuncture of the jugular vein at multiple time points and were analyzed using a 4% paraformaldehyde (2% paraformaldehyde) containing K3EDTA as an anticoagulant. Blood samples were obtained before dosing, and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 7, 12, and 24 hours after dosing. Blood samples were stored at ambient room temperature prior to automated differential analysis.

[0129] Body weight was measured before dosing on the day of test sample administration. Animals were observed at least once a day and at the time of blood sampling.

[0130] Hematologic parameters include the following:

[0131] White blood cell count (WBC)

[0132] White blood cell differential count (absolute and relative)

[0133] Neutrophils

[0134] Lymphocytes

[0135] Monocytes

[0136] Eosinophils

[0137] Basophils

[0138] Large unstained cells (LUC)

[0139] Hematocrit (HCT)

[0140] Hemoglobin (HGB)

[0141] Mean corpuscular hemoglobin (MCH)

[0142] Mean corpuscular hemoglobin concentration (MCHC)

[0143] Mean corpuscular volume (MCV)

[0144] Platelet count (PLT)

[0145] Red blood cell count (RBC)

[0146] result

[0147] Figure 8The effect of X4P-001 on WBC and absolute neutrophil counts and absolute lymphocyte counts was shown. The WBC increased the most 4 to 12 hours after administration. At the 15 and 35 mg / kg dose levels, the peak increase ranged from 1.8 to 2.9 times higher than the baseline value, and a slightly lower increase (1.5 times) was observed at the 5 mg / kg dose level. Although limited by the small sample size, these results indicate that the maximum increase can be achieved at higher dose levels. At 24 hours, WBC counts, neutrophil counts, and lymphocyte counts remained elevated at the 15 and 35 mg / kg dose levels, with evidence of returning to baseline. No other hematological effects were observed.

[0148] 28-day oral (capsule) study in beagles with a 14-day recovery period

[0149] A 28-day GLP oral (capsule) toxicology study was conducted in male and female beagle dogs using X4P-001 and observing hematological effects, X4P-001 was administered twice daily by oral capsule (at least 7 hours apart) for 28 days. A subset of treated animals was evaluated after a 14-day recovery period. Table 3 lists the protocol design and Table 4 lists the evaluation schedule.

[0150] Table 3: Protocol Design for the 28-Day Toxicity Study in Dogs

[0151]

[0152] Table 4: Program evaluation and timeline

[0153] evaluate schedule Study duration Day 10 to Day 42 treat Day 10 to Day 28, twice a day Clinical observation Twice a day Food consumption Once a day weight Once a week <![CDATA[Vital signs a > Pre-medication adaptation phase; final medication week; final recovery week Ophthalmology Before medication and during the 4th week Electrocardiographic evaluation Before medication and within 4 weeks, ~1 hour after first daily dose <![CDATA[Clinical pathology b > Before medication, day 10, day 2; after medication, day 29 (all groups), day 42 (recovery group only) <![CDATA[Autopsy c > Day 29, terminate; Day 42, resume

[0154] a. Vital signs include heart rate, blood pressure, and body temperature.

[0155] b. Clinical pathology including hematology, coagulation, serum and urine tests (completed only once before medication)

[0156] c. Necropsy studies included organ weights, macroscopic and microscopic observations, including a 500-cell bone marrow differential count.

[0157] As shown in Table 5 below, increases in absolute counts of neutrophils, lymphocytes, and monocytes were observed at termination (Day 28); these were greater in females and more likely to be statistically significant. These changes are considered consistent with the pharmacological effects of X4P-001. After a 14-day recovery period (only the 100 mg / kg dose group evaluated), all hematological results returned to within normal levels.

[0158] Table 5: Hematological Findings at Termination of the 28-Day Oral Toxicity Study in Dogs

[0159]

[0160]

[0161] abs, absolute; Compared with control animals of the same sex

[0162] Hematological effects of X4P-001 in mice

[0163] Further studies were performed to determine whether X4P-001 mobilizes progenitor / stem cells in mice. All experiments were performed in C3W / He J mice. X4P-001 and AMD3100 / plerixafor were administered by a single subcutaneous injection at the doses described below. The mobilization capacity of X4P-001 was assessed by the number of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotent (CFU-GEMM) progenitor cells per microliter of blood. Progenitor cells were stimulated to form in vitro colonies with a combination of 1 enzyme activity unit / microliter rhu EPO, 50 ng / ml rmuSLF, 5% by volume of pokeweed mitogen mouse spleen cell conditioned medium (PWMSCM), and 0.1 mmol / liter hemin. Plates were scored after incubation for 7 days at 37°C, 5% CO2, reduced (5% CO2), and humidified chambers.

[0164] result

[0165] After a single subcutaneous injection, X4P-001 mobilizes progenitor cells in C3H / HeJ mice. In the first experiment (data shown in Table 6), mice received a dose of 5 mg / kg-, and the number of progenitor cells in the circulating blood was measured at different time points (0.25, 0.5, 1, 2, 6 and 24 hours). The peak of nucleated cell mobilization occurred approximately 1 to 2 hours after injection. The peak increase of CFU-GM, BFU-E and CFU-GEMM exceeded the control (saline injection) by 4.21 times (30 minutes), 2.49 to 2.54 times (30 to 60 minutes) and 2.58 to 2.67 times (30 to 60 minutes), respectively.

[0166] Table 6: X4P-001 Time Course of Progenitor Cell Mobilization

[0167]

[0168]

[0169] Animals per group = 3, control group = 1, total animals = 21

[0170] The X4P-001 dose response was performed by measuring the number of circulating progenitor cells in the blood 1 hour after injection at different doses (1.5, 2.5, 5, 10 and 20 mg / kg). As shown in Table 7, there appears to be an upper limit to the number of progenitor cells that can be mobilized with X4P-001, as exemplified by the fold increase in CFU-GM. The number of CFU-GM in the circulating blood increased dose-dependently, with peak fold increases of 6.0 to 7.7 times that of the control at 5 to 20 mg / kg. At 10 mg / kg, peak fold increases of 2.3 and 3.8 times were noted for BFU-E and CFU-GEMM, respectively. At doses of X4P-001 below 5 mg / kg, the fold increase in the number of BFU-E and CFU-GEMM was not statistically significant.

[0171] Table 7: Dose response in C3H / HeJ mice

[0172]

[0173] Animals per group = 3, control group 1, total animals = 18

[0174] The final experiment was carried out to compare the progenitor cell mobilization ability of X4P-001 and AMD3100 / plerixafor. Two drugs were administered subcutaneously at a dosage of 5 mg / kg, and the progenitor cell quantity in the circulating blood was measured for AMD3100 at a single 1 hour time point (with the mobilization peak of AMD3100, data not shown)--it was compared to X4P-001 at 0.25, 0.5, 1 and 2 hours after injection. As shown in Table 8, the increase multiples of CFU-GM, BFU-E and CFU-GEMM were compared, and AMD3100 made each maximum increase of 9.11, 3.12 and 4.35, while each mobilization peak with X4P-001 was 3.56, 2.84 and 3.21.

[0175] Table 8: X4P-001 Time Course Compared to ADM3100 / Plerixafor (Dose 5 mg / kg)

[0176]

[0177] Animals per group = 3, control group = 1, total animals = 18

[0178] Based on the conclusions of in vivo studies

[0179] Single oral doses of X4P001 at 5, 15 and 35 mg / kg in beagle dogs increased levels of total circulating WBC, neutrophils and lymphocytes. Increases were evident at 4 hours and typically peaked at 12 hours, occasionally earlier. At 5 mg / kg, all three cell counts increased to 1.47 times baseline. At 15 mg / kg, neutrophils increased to 1.8 times and lymphocytes increased to 2.9 times; and at 35 mg / kg, neutrophils to 2.7 times and lymphocytes to 1.9 times.

[0180] In the multiple-dose toxicity study in dogs, hematologic effects after 28 days were qualitatively and quantitatively consistent with those found in the single-dose study in beagle dogs.

[0181] In C3H / HeJ mice, X4P-001 dose-dependently increased the number of circulating progenitor cells up to doses of 5 to 10 mg / kg sc.

[0182] Example 2: Clinical: Patients to be treated:

[0183] Patients that can be treated according to the present invention include patients who have been diagnosed with WHIMS or with MKX; and patients who present characteristic mutations in their CXCR4 gene. Other patients that can benefit from the present invention may include individuals who present the following screening criteria:

[0184] Neutropenia (ANC ≤ 400 or ≤600 / μL) and / or lymphocytopenia (ALC ≤650 or ≤1000 / μl)—the latter is not a feature of other chronic neutropenias;

[0185] Neutropenia and chronic warts;

[0186] Neutrophilic bone marrow sparing in bone marrow aspirate;

[0187] Patients meeting the above criteria are screened for MKX genes. Patients with characteristic mutations in CXCR4 are most likely to benefit from treatment according to the present invention.

[0188] Therefore, the effect of X4P-001 is expected to be greatest in patients with neutrophilic myeloretention with CXCR4 mutations. In addition, patients who may benefit from treatment according to the present invention include individuals presenting the following screening criteria:

[0189] 1. Have a confirmed CXCR4 mutation consistent with WHIM syndrome; and

[0190] 2. ANC ≤ 400 in at least two separate blood samples collected over a period of up to 14 days or ≤600 / μL, or ALC ≤650 or ≤1000 / μL, or both.

[0191] 3. One of the following findings:

[0192] Neutrophilic bone marrow sparing on bone marrow aspirate or biopsy

[0193] ●Peripheral WBC count (≥2 independent samples, obtained in the absence of signs or symptoms of acute infection and when not receiving G-CSF or GM-CSF in the past 7 days) showing an absolute neutrophil count <900 cells / microliter and / or an absolute lymphocyte count <1500 cells / microliter.

[0194] Examples of candidate endpoints based on 6 months of treatment compared to the first 6 months without treatment include:

[0195] ● 50% reduction in hospitalizations

[0196] ● 50% reduction in infections requiring a course of systemic antibiotics

[0197] ●50% reduction in the area of ​​skin warts involved

[0198] ●Persistent increase in circulating neutrophils (eg, ANC >600 cells / microliter; ANC >800 cells / microliter; ANC >1000 cells / microliter; or ANC >1200 cells / microliter in at least 85% of evaluations)

[0199] ●Persistent increase in circulating lymphocytes (eg, ALC >1000 cells / microliter; ALC >1200 cells / microliter; or ALC >1500 cells / microliter in at least 85% of evaluations)

[0200] - Achieving a predefined level of protective antibodies in response to at least 2 previously administered licensed vaccines that did not reach that level.

[0201] ● Reduce the number of days missed from work or school due to infection by 50%

[0202] ●Continued increase in circulating neutrophils.

[0203] Not all endpoints apply to all patients, just as not all WHIM patients present with the same clinical picture. However, all patients show at least one clinical and one laboratory marker.

[0204] Patients are started on treatment, preferably with oral X4P-001 25 mg once daily, 25 mg twice daily, or 50 mg once daily. In case of increasing toxicity, dose reductions are prescribed (which may be by increasing intervals; e.g., every other day or twice a week), or in case of inadequate response, dose increases are prescribed (e.g., to >50 mg once daily or higher daily doses, e.g., 100 mg / day or 150 mg / day).

[0205] An exemplary initial dose is via X4P-001 25 mg capsules, administered orally in the morning on an empty stomach, without food or drink (except water) after midnight and for 2 hours after dosing. In a twice daily dosing regimen, the capsules are preferably administered orally 12 hours apart.

[0206] Example 3: Clinical treatment plan

[0207] Medication regimen for patients with WHIM syndrome:

[0208] X4P-001 was administered orally at a defined dose of 25 mg or 50 mg per day. Patients were instructed regarding the dosing schedule and requirements regarding food or beverages near dosing times.

[0209] Dosing schedule. The first daily dose is taken in the morning. For two daily doses, the doses should be taken 12 hours apart. Doses should be taken at the same time each day ± 2 hours.

[0210] Food-Related Restrictions. Absorption is affected by food; provide patients with the following instructions:

[0211] For morning use:

[0212] - No food or drink (except water) after midnight until time of medication

[0213] - No food or drink (except water) within 2 hours after taking this medication.

[0214] The dosing of X4P-001 may be adjusted by the clinician as appropriate. The dose of X4P-001 may be reduced at the clinician's discretion. If a patient receiving X4P-001 experiences an adverse event of grade > 2, the dose of X4P-001 may be reduced at the clinician's discretion. If the patient successfully completes the first 2 to 4 weeks of treatment without experiencing any adverse events greater than grade 2, the daily dose of X4P-001 may be increased consistent with the clinician's discretion.

[0215] Alternative medication regimens for patients with WHIM syndrome

[0216] Measure the patient's initial absolute neutrophil count (ANC) (neutropenia) (ANC < 400 or <600 / μL) and / or absolute lymphocyte count (ALC) (lymphocytopenia) (ALC <650 or <1000 / μl). [Note - the latter is not a feature of other chronic neutropenias]. If the patient shows an ANC less than 400 or Less than 600 cells / μL; and / or ALC still less than 650 or Less than 1000 cells / μL, treatment with X4P-001 was initiated. Patients were initially treated with X4P-001 25 mg orally once daily, 25 mg orally twice daily, or 50 mg orally once daily. In case of toxicity, dose reduction (which may be by increasing the interval, e.g., every other day or twice a week) or discontinuation of administration was prescribed, or in case of inadequate response, dose increase (e.g., to >50 mg per day or higher daily dose) was prescribed.

[0217] Monitor ANC and ALC monthly or preferably every two weeks. or >600 cells / μL; and / or ALC>650 or >1000 cells / μL, the patient will continue with the initial daily dosing regimen. If the ANC remains below 400 or Less than 600 cells / μL; and / or ALC still less than 650 or If the level is below 1000 / μL and the patient does not experience severe adverse reactions, the patient's dose will be increased to 25 mg or 50 mg per day [or 25 mg orally twice daily; 12 hours apart].

[0218] Patients taking increasing doses of 50 mg / μL per day will continue to be monitored monthly or preferably every two weeks. or ≥600 cells / μL; ALC≥650 or ≥1000 cells / μL (no serious adverse reactions), the patient will continue with the increased dose regimen. If the ANC remains below 400 or Less than 600 cells / μL; and / or ALC still less than 650 or Below 1000 cells / μL, (and the patient presents with no serious adverse events), the patient's dose will be further increased to an additional 25 mg or 50 mg per day.

[0219] The above process of increasing the daily dose regimen can be repeated until the patient reaches an ANC ≥ 400 or ≥600 cells / μL; and / or ALC ≥650 or ≥1000 cells / μL (no serious adverse reactions); or until the patient is treated with the maximum tolerated daily dose.

[0220] Alternatively, relative to 400 or 600 / μl and 650 or ANC and ALC will be analyzed as area under the curve (AUC) at a pre-specified clinically meaningful threshold of ≥1000 cells / μL. The 24-hour AUC will be calculated using the trapezoidal method, with areas above the threshold as positive and areas below the threshold as negative. ANC <2000 cells·hour / μl or AUC ALC Patients with <5000 cells·hours / μL will be evaluated monthly or biweekly and will have their daily dose of X4P-001 increased by 25 mg or 50 mg, up to a maximum dose of 150 mg QD. Because ANC and ALC in WHIM patients are significantly affected by acute infections, either alone or with treatment with antibiotics, G-CSF, or IVIG, AUC monitoring should be delayed or discontinued in patients with acute infections until such patients remain afebrile for at least 2 weeks.

[0221] If a patient experiences an adverse reaction at any time, a dose reduction (i.e., a lower dose and / or increased intervals between drug administrations) is prescribed, or administration is discontinued. In addition, the attending physician may use his or her professional judgment and discretion to determine the starting dose and how best to titrate the appropriate dose of X4P-001 for any individual patient.

[0222] An exemplary composition of an X4P-001 25 mg capsule that may be used is shown in Table 9 below.

[0223] Table 9: Quantitative Composition of Exemplary X4P-001 25 mg Capsules

[0224] Components Reference Standards Function Amount (mg / capsule) weight% X4P-001 internal Active ingredients 25.0 14.7 Microcrystalline Cellulose NF Thinner 132.7 78.1 Croscarmellose Sodium NF Disintegrants 10.2 6.0 Sodium stearyl fumarate NF Lubricants 1.7 1.0 Colloidal Silica USP Glidants 0.4 0.2 total 170.0 100.0 Hard gelatin capsules, size 1 USP Package NA NA

[0225] Example 4: Evaluation of therapeutic effects

[0226] Circulating white blood cells

[0227] Analysis of whole blood samples:

[0228] CBC and absolute white blood cell differential counts by standard laboratory methods, including WBC counts, including absolute numbers of lymphocytes, neutrophils, and CD34+ cells. Number and percentage of patients achieving ANC>1,500 cells / μL; ALC>900 cells / μL. Absolute increase in blood neutrophil counts from each subject's pre-treatment baseline, including the maximum observed within hours of dosing; and the maximum initial dose observed on a stable drug administration regimen. These results are compared to data from healthy adults administered X4P-001.

[0229] Peripheral blood mononuclear cell (PBMC) subsets by flow cytometry are shown in Table 10 below.

[0230] Table 10: Candidate subsets of circulating lymphocytes and monocytes

[0231]

[0232] Immunoglobulins and specific antibodies

[0233] Serum samples were analyzed for levels of total IgG, IgG subclasses, IgA, and IgM, as well as levels of selected specific antibodies to common vaccine antigens (Table 11).

[0234] Table 11: Common vaccines that elicit protective antibodies in the age range of initial administration

[0235]

[0236] The following parameters were checked:

[0237] Increased levels of IgG, IgA, and IgM

[0238] For patients with subprotective titers of specific antibodies to an approved microbial vaccine, clinicians and patients can decide to revaccinate and analyze the development of protective titers after vaccination.

[0239] Bone marrow aspirate

[0240] Bone marrow aspirates were obtained from consenting patients at screening, after 4 and 20 weeks of treatment. The aspirates were reviewed by a blinded hematopathologist and graded for cellularity and neutrophilic bone marrow sparing. If sufficient material was available, the samples were analyzed for markers of neutrophil apoptosis and lymphocyte subsets.

[0241] The following parameters were checked:

[0242] ●Reduction of excess cells

[0243] ● Decreased proportion of apoptotic WBCs

[0244] Clinical evaluation

[0245] Warts. Monitor warts by photographing and / or recording the location, number, and size of lesions.

[0246] Infections. Temperatures were taken twice daily for signs or symptoms of infection resulting in fever, prompting a physician visit, requiring antibiotics, or associated with hospitalization and compared with the year before treatment.

[0247] Pharmacokinetic evaluation

[0248] If desired, a pharmacokinetic assessment of X4P-001 plasma levels of blood samples can be performed. Blood samples are collected at predetermined times. Samples are analyzed for X4P-001 concentration using reverse phase high performance liquid chromatography (RP-HPLC) with MS / MS detection. The validated range of this bioanalytical method in plasma is 30 ng / mL to 3,000 ng / mL.

[0249] Pharmacokinetics (PK) and Pharmacodynamics (PD). To evaluate the pharmacokinetic properties of therapy with X4P-001 (levels of X4P-001), PK samples were obtained in all patients in Part A as follows

[0250] ● Day 1: Before medication; 30, 60, 90 minutes (±10% each) and 2, 3, 4 hours (±15 minutes each) after medication

[0251] ● Week 5 visit: Before medication; 30, 60, 90 minutes (±10% each) and 2, 3, 4, 8 hours (±15 minutes each) after medication

[0252] ●Week 9 and Week 13 Visits: Before medication.

[0253] The visit was scheduled early in the day, and patients were instructed to come to the clinic on an empty stomach and not take their morning dose of X4P-001.

[0254] Using AUC, C 最大 and C 最小 Descriptive statistics were used to analyze PK by patient and dose regimen in the previous week.

[0255] Additional sampling days could be added if results indicated (a) continued accumulation beyond Week 5 or (b) a specific PK parameter was associated with an adverse effect.

[0256] PD samples were collected at the Day 1 and Week 5 visits concurrently with scheduled PK samples (see above) for:

[0257] Total white blood cell (WBC) count

[0258] Circulating CD34+ positive cell count

[0259] - Assessment may include analysis of samples of PBMC subsets by flow cytometry.

[0260] If sample yield permits, other investigational immune regulatory subsets can be analyzed (see Table 11).

[0261] Of course, the attending physician may apply his or her professional judgment and discretion, as well as any established standards of care, as to what assessment parameters (eg, desired levels of ANC and ALC) should be used in determining the treatment regimen for any individual patient.

[0262] References

[0263] Baggiolini; 1998. Chemokines and leukocyte traffic. Nature 392: 565-568.

[0264] Balabanian et al. 2005. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105:2449-2457.

[0265] Balabanian et al. 2012. Proper desensitization of CXCR4 is required for lymphocyte development and peripherial compartmentalization in mice. Blood 119:5722-5730.

[0266] Beaussant-Cohen et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71.

[0267] Bohinjec, 1981. Myelokathexis: chronic neutropenia with hyperplastic bone marrow and hypersegmented neutrophils in two siblings. Blood 42:191-196.

[0268] Broxmeyer. A WHIM satisfactorily addressed. Blood 2014;123:2286-8.

[0269] Cao et al. Effect of Low-Dose Ritonavir on the Pharmacokinetics of the CXCR4 Antagonist AMD070 in Healthy Volunteers. Antimicrob Agents Chemother. 2008;52:1630-1634.

[0270] Crump et al. 1997. Solution structure and basis for functional activity of stromal cell derived factor-1; dissociation of CXCR4 activationfrom binding and inhibition of HIV-1. EMBO J. 16:6996-7007.

[0271] Dale et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 2011; 118: 4963-4966.

[0272] Dale et al. The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Support Cancer Ther. 2006;3:220-31.

[0273] Doranz 1997. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1). Immunol Res. 16:15-28.

[0274] Dotta, 2011. Clinical and genetic features of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. Current Molecular Medicine; 11: 317-325.

[0275] Galsky et al. 2014. A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer. Clin Cancer Res. doi: 10.1158 / 1078-0432.CCR-13-2686.

[0276] Gulino et al. 2004. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104: 444-452.

[0277] Hendrix et al. 2004. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection. J Acquir Immune Defic Syndr. 37: 1253-1262.

[0278] Hernandez et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nature Genetics 2003;34:70-74.

[0279] Kawai et al. 2005. Enhanced function with decreased internalization of carboxy-terminustruncated CXCR4 responsible for WHIM syndrome. Exp Hematol. 33:460-468.

[0280] Kawai and Malech; 2009. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol. 16:20-26.

[0281] Kawai et al.; WHIM syndrome myelokathexis reproduced in the NOD / SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood 2007;109:78-84. Epub 2006 Aug 31.

[0282] Lagane et al. 2008. CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 112:34-44.

[0283] Lapidot and Petit; 2002. Current understanding of stem cell mobilization: theroles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol. 30:973-981.

[0284] Ma. 1999. The chemokine receptor CXCR4 is required for retention of B lineage and granulocytic precursors in the bone marrow microenvironment. Immunity 10: 463-471.

[0285] Martin et al. Births in the United States, 2013. National Center for Health Statistics Data Brief. No. 175: December 2014.

[0286] McCormick et al. 2009. Impaired recruitment of Grk6 and beta-Arrestin2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 mutant receptor. PLoS One 4:e8102.

[0287] a-McDermott et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011;118:4957-62.

[0288] b-McDermott et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014;123:2308-16.

[0289] Moshi et al. 2012. The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacology 83: 472-479.

[0290] Moyle et al. Proof of Activity with AMD11070, an Orally Bioavailable Inhibitor of CXCR4-Tropic HIV Type 1. Clin Infect Dis. 2009;48:798-805.

[0291] Nyunt et al. Pharmacokinetic Effect of AMD070, an Oral CXCR4 Antagonist, on CYP3A4 and CYP2D6 Substrates Midazolam and Dextromethorphan in Healthy Volunteers. J Acquir Immune Defic Syndr. 2008;47:559-565.

[0292] Stone et al.; Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human Subjects. Antimicrob Agents Chemother. 2007;51:2351-2358.

[0293] Ward and Dale. Genetic and molecular diagnosis of severe congenital neutropenia. Curr Opin Hematol. 2009;16:9-13.

[0294] Wong, 2008. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74: 1485-1495.

[0295] Zlotnik and Yoshie 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.

[0296] Zuelzer: “Myelokathexis”-A New Form of Chronic Granulocytopenia. Report of a case. N Engl J Med 1964, 270:699-704.

[0297] Research Report

[0298] A 28 day Oral (Capsule) Toxicity Study in the Male and Female Beagle Dog with a 14 day Recovery (Study CTBR77401): November 2003.

[0299] Pharmacology & Toxicology of AMD11070: Hematological Effects in the Male Beagle Dog. AnorMED, Inc. March 18, 2003 (Study No. AOM0031).

[0300] Hematological Effects of AMD11070 in Mice. Indiana University School of Medicine, March 14, 2003 (Study No. AOM0033).

[0301] ACTG (DIAIDS) Protocol A5210. Unpublished data.

[0302] Internet References:

[0303] George Diaz, Virginia Gulino WHIM syndrome. Orphanet Encyclopedia, June 2004; http: / / www.orpha.net / data / patho / GB / uk-Whim.pdf

[0304] NORD (National Organization for Rare Disorders) 2015: https: / / rarediseases.org / rare-diseases / whim-syndrome

[0305] Office of Rare Diseases: https: / / rarediseases.info.nih.gov / gard / 9297 / whim- syndrome / resources / 1

[0306] Orphanet, WHIM syndrome: http: / / www.orpha.net / consor / www / cgi-bin / OC_ Exp.php? lng=EN&Expert=51636

[0307] Last updated October 2014

[0308] U.S. Census Bureau: http: / / www.census.gov / quickfacts / table / PST045214 / 00

[0309] Last revised June 2015.

Claims

1. A use of X4P-001 or a pharmaceutically acceptable salt thereof or a composition for the manufacture of a medicament for treating WHIM syndrome in a patient in need thereof, wherein the medicament causes an increase in ANC levels to at least 600 cells / microliter in at least 85% of the assessments and the medicament causes an increase in ALC to at least 1000 cells / microliter in at least 85% of the assessments; wherein X4P-001 or a pharmaceutically acceptable salt thereof is orally administered once or twice daily at a dose of 20 mg / day to 600 mg / day.

2. The use according to claim 1, wherein the X4P-001 is administered at a dose of 20 mg / day to 600 mg / day.

3. The use according to claim 1, wherein the patient presents with warts.

4. The use according to any one of claims 1 to 3, wherein the cells taken from the patient express a mutant form of CXCR4.

5. The use according to any one of claims 1 to 3, wherein cells taken from the patient exhibit increased expression of CXCR4.

6. The use according to any one of claims 1 to 3, wherein a biological sample is obtained from the patient and the amount of a biomarker associated with a disease is measured.

7. The use according to claim 6, wherein the biological sample is a blood sample.

8. The use according to claim 7, wherein the disease-associated biomarker is circulating CXCR4.

9. The use according to any one of claims 1 to 3, wherein the X4P-001 or a pharmaceutically acceptable salt thereof is orally administered once a day.

10. The use according to any one of claims 1 to 3, wherein the X4P-001 or a pharmaceutically acceptable salt thereof is orally administered twice a day.

11. Use of X4P-001 or a pharmaceutically acceptable salt thereof or a composition for the manufacture of a medicament for treating WHIM syndrome in a patient in need thereof, wherein the medicament is administered to the patient in an amount effective to increase the absolute neutrophil count ANC to a level greater than or equal to 600 / μl and the absolute lymphocyte count ALC to a level greater than or equal to 1000 / μl; wherein X4P-001 or a pharmaceutically acceptable salt thereof is orally administered once or twice a day at a dose of 20 mg / day to 600 mg / day.

12. The use according to claim 11, wherein the patient initially presents with an ANC of less than 600 cells / microliter and / or an ALC of less than 1000 cells / microliter prior to treatment with X4P-001.

13. The use according to claim 11, wherein prior to treatment with X4P-001, the patient initially exhibited an ANC of less than 400 cells / microliter and / or an ALC of less than 650 cells / microliter.

14. The use according to any one of claims 1 to 3 or 10 to 13, wherein the medicament causes an increase in the level of protective antibodies in the patient in response to a vaccine.